White Paper

Is Your CMO Ready For Serialization And Aggregation?

Source: AbbVie

By Lloyd Mager

logistics_450x300

In the continuous improvement environment of pharmaceutical development and manufacturing, efforts to secure and enhance the supply chain include serialization and aggregation to exert more control over packaging, shipping, and distribution to enable traceability of finished drug products.

The U.S. Food and Drug Administration is halfway through its 10-year period to establish “an interoperable, electronic product tracing system at the package level” as part of the Drug Supply Chain Security Act (DSCSA). The purpose of the 2013 act is to identify suspect or illegitimate products in the supply chain, while also enabling manufacturers to notify FDA of any potentially dangerous products in supply.

Most recently, in February 2018, as part of DSCSA, FDA issued draft guidance on standards for the “interoperable exchange of transaction information, transaction history and transaction statements (product tracing information)” among trading partners. These exchanges must be electronic-only by 2023.

“With a dedicated traceability operation within the company, and serialization efforts in place, AbbVie has prepared a long-term strategy to address aggregation.”

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: